- Home
- KGEI vs SIGA Comparison
KGEI vs SIGA Comparison
Compare KGEI & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KGEI | SIGA |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.0M | 223.8M |
| IPO Year | 2009 | 2016 |
Fundamental Metrics
Financial Performance| Metric | KGEI | SIGA |
|---|---|---|
| Price | $6.10 | $3.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 136.4K | ★ 823.3K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.13 |
| Revenue | N/A | N/A |
| Revenue This Year | $32.37 | N/A |
| Revenue Next Year | $4.72 | $224.81 |
| P/E Ratio | ★ $7.94 | $22.85 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.35 | $2.83 |
| 52 Week High | $6.61 | $9.45 |
Technical Indicators
Market Signals| Indicator | KGEI | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 68.09 | 43.83 |
| Support Level | $4.93 | $3.01 |
| Resistance Level | $6.61 | $4.84 |
| Average True Range (ATR) | 0.24 | 0.13 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 92.96 | 50.00 |
Price Performance
Historical ComparisonAbout KGEI Kolibri Global Energy Inc.
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. The company derives a majority of its revenue from the United States.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.